Kings Path Partners LLC Purchases 16,570 Shares of BioLife Solutions, Inc. $BLFS

Kings Path Partners LLC purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the third quarter, Holdings Channel.com reports. The firm purchased 16,570 shares of the medical equipment provider’s stock, valued at approximately $644,000.

Several other institutional investors have also recently made changes to their positions in BLFS. Nisa Investment Advisors LLC raised its position in shares of BioLife Solutions by 13.3% in the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the medical equipment provider’s stock worth $86,000 after buying an additional 260 shares in the last quarter. Abel Hall LLC purchased a new position in BioLife Solutions during the third quarter worth about $224,000. GAMMA Investing LLC grew its position in BioLife Solutions by 7.2% during the third quarter. GAMMA Investing LLC now owns 9,647 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 651 shares in the last quarter. Tidal Investments LLC purchased a new position in BioLife Solutions during the second quarter worth about $819,000. Finally, WINTON GROUP Ltd bought a new position in BioLife Solutions in the 2nd quarter worth about $201,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

BLFS opened at $38.61 on Thursday. The stock’s 50 day simple moving average is $37.11 and its 200 day simple moving average is $29.86. BioLife Solutions, Inc. has a 1 year low of $17.86 and a 1 year high of $39.76. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.82.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. The business had revenue of $28.47 million for the quarter, compared to analysts’ expectations of $27.80 million. As a group, sell-side analysts anticipate that BioLife Solutions, Inc. will post 0.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, September 21st. William Blair set a $31.00 price target on BioLife Solutions in a research report on Thursday, July 23rd. TD Cowen lowered BioLife Solutions from a “buy” rating to a “hold” rating and cut their price objective for the stock from $33.00 to $31.00 in a report on Wednesday, July 22nd. Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Craig Hallum cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $31.38.

BioLife Solutions Profile

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.